XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).

Cancer Commun (Lond) · 2022 · PMC9017757 · PMID 35212487

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

In recent years, there has been a decreasing trend in the application of triplet regimens in palliative treatment, but EOX was still used in clinical practice and trials [ 14 , 15 ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.